Comparison of effect of interferon-alpha, lamivudine monotherapy and combination therapy in chronic hepatitis B / 대한내과학회지
Korean Journal of Medicine
;
: 342-348, 2001.
Artículo
en Coreano
| WPRIM
| ID: wpr-92803
ABSTRACT
BACKGROUND:
Alpha-interferon achieves HBeAg seroconversion in about 30 to 40% of patients with chronic hepatitis B, and recently discovered lamivudine, an oral nucleoside analogue, inhibits hepatitis B virus replication and reduces hepatic necroinflammation in patients with chronic hepatitis B effectively. In this study, we compared the efficacy and safety of alpha-interferon, lamivudine and their combination regimen.METHODS:
Fourty chronic hepatitis B patients, who were diagnosed through HBV DNA, HBeAg positivity, alanine aminotransferase elevation, and liver biopsy were enrolled in this study. Twelve patients were treated with 500 MU of alpha-interferon subcutaneously 3 times a week for 6 months, 9 patients were treated with 150 mg of lamivudine and alpha-interferon, and 19 patients were treated with 150 lamivudine daily for 6 months.RESULTS:
After treatment, all of the three groups showed rapid decline in HBV DNA level, but lamivudine group showed more clearance of HBV DNA than interferon group (alpha-interferon 75%, combination group 89%, lamivudine group 100%, respectively) (p=0.04). HBeAg seroconversion rate was 25% for interferon group, 11% for combination group, 26% for lamivudine group, showing no difference between three groups (p=0.705). Mean serum ALT level and rate of ALT normalization during therapy showed no differnece (83% for interferon group, 78% for combination group, 84% for lamivudine group).CONCLUSION:
It is suggested that the efficacy of combination interferon/lamivudine therapy appears disappointing and further study should be done for appropriate combination or monotherapy of lamivudine for patients with chronic hepatitis B.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Biopsia
/
ADN
/
Virus de la Hepatitis B
/
Interferones
/
Interferón-alfa
/
Lamivudine
/
Hepatitis B Crónica
/
Alanina Transaminasa
/
Antígenos e de la Hepatitis B
/
Hepatitis Crónica
Límite:
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Medicine
Año:
2001
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS